U.S. Markets close in 36 mins
  • S&P 500

    4,543.55
    -23.45 (-0.51%)
     
  • Dow 30

    34,259.06
    -224.66 (-0.65%)
     
  • Nasdaq

    15,340.40
    -197.29 (-1.27%)
     
  • Russell 2000

    2,173.05
    -25.86 (-1.18%)
     
  • Crude Oil

    65.51
    -0.67 (-1.01%)
     
  • Gold

    1,780.90
    +4.40 (+0.25%)
     
  • Silver

    22.23
    -0.59 (-2.56%)
     
  • EUR/USD

    1.1317
    -0.0022 (-0.1924%)
     
  • 10-Yr Bond

    1.4340
    -0.0090 (-0.62%)
     
  • Vix

    27.65
    +0.46 (+1.69%)
     
  • GBP/USD

    1.3270
    -0.0031 (-0.2349%)
     
  • USD/JPY

    112.7920
    -0.3880 (-0.3428%)
     
  • BTC-USD

    57,154.63
    -326.43 (-0.57%)
     
  • CMC Crypto 200

    1,458.17
    -10.92 (-0.74%)
     
  • FTSE 100

    7,168.68
    +109.23 (+1.55%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

Fastly, PagerDuty, Johnson & Johnson, Moderna and Pfizer highlighted as Zacks Bull and Bear of the Day

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·13 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

For Immediate Release

Chicago, IL – October 22, 2021 – Zacks Equity Research Shares of Fastly, Inc. FSLY as the Bull of the Day, PagerDuty, Inc. PD as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Johnson & Johnson JNJ, Moderna, Inc. MRNA and Pfizer Inc. PFE.

Here is a synopsis of all five stocks:

Bull of the Day:

Fastly is a $6 billion provider of infrastructure software that powers cloud computing, image optimization, security, edge computer technology and broadband streaming solutions. They are considered part of a cloud niche called Content Delivery Networks, or CDNs.

The company was an emerging cloud darling last year as demand for its services greatly expanded during the pandemic's work-from-home epidemic. Big customers like TikTok and Amazon had adopted Fastly's high-bandwidth capabilities and shares traded above $120, sporting a big cap valuation of nearly $15 billion, with projected sales of only $300 million.

But the earnings outlook started to turn negative after its Q4'20 report in February and shares fell back to $60 during the March stock market slump. Q1'21 was worse and shares dropped 27% on May 6 on 32 million shares.

Then June brought the real calamity in the form of a network outage which may have caused a major customer to go elsewhere. On Tuesday June 8, several news outlets reported that countless websites suffered a brief outage due to a glitch at the popular CDN provider.

According to TechCrunch, Reddit, Spotify, Quora, PayPal, Vimeo, Shopify, CNN, The Guardian, The New York Times, BBC and Financial Times were among websites that faced the outage.

Outlook Softens Again

Here's what I wrote in August for my FSLY Bear of the Day article, following the company's Q2 report...

EPS estimates just got slashed again in the last week following their Q2 earnings report on August 4, with the 2021 profit consensus cratering 47.6% from a loss of 42 cents to -62 cents, representing a -244% annual wipeout.

And next year's outlook imploded a whopping 85% from a loss of 26 cents to -48 cents.

One thing that stood out about the August 5 price action was another big drop to new 52-week lows below $35 on massive volume of 50 million shares. It looked like capitulation of the last FSLY bulls to me, and I started getting interested in a potential turn-around.

Analysts Throw in the Towel

Part of that capitulation was due to big overreactions from the spreadsheet jockeys...

Craig Hallum on 8/5: Analyst Jeff Van Rhee lowered the firm's price target on Fastly to $42 from $55 and kept a Hold rating on the shares. He acknowledged the in-line quarter, but adjusted his model estimates downward because the company missed so meaningfully on the forward guide.

DA Davidson on 8/5: Analyst Rishi Jaluria downgraded Fastly to Neutral from Buy with a price target of $33, down from $60. The analyst cited the company's Q2 revenue miss and reduced FY21 guidance as June outages resulted in a top-10 customer and several others pulling all traffic from its network. Jaluria also noted management's commentary that there have been delays in those same new customer ramps this quarter, unrelated to the June outage.

Citigroup on 8/5: Analyst Tyler Radke lowered the firm's price target on Fastly to $33 from $46 and kept a Sell rating on the shares. Fastly's "challenging 2021 worsened considerably" with the Q2 results that fell well short of expectations on nearly every metric. The company's usage-based model has shown its downside and unpredictability, and with significant fallout from the outage, it could take multiple quarters to correct, according to Radke.

William Blair on 8/5: Analyst Jonathan Ho downgraded Fastly to Market Perform from Outperform without a price target. Fastly reported a "subpar quarter, impacted by a service outage in June that led the company to issue credits, a top 10 customer departure, and slower ramp-up of existing traffic." Ho also noted that Fastly saw an unrelated slowdown in onboarding of some new customer traffic. Given the "uncertainty and unpredictability in the business," he believes the stock is likely to remain range-bound over the medium term as management "has a lot of work to do to rebuild credibility."

Piper Sandler on 8/5: Analyst James Fish lowered the firm's price target on Fastly to $32 from $45 and kept a Neutral rating on the shares. "The stock is down 20% post-earnings following only an inline quarter, weaker than anticipated organic trends given the June outage, and Q3 and 2021 guidance missing by 15% and 10%, respectively."

Get Ready to Buy FSLY

This week I started a very small position in FSLY after the company announced a new patent and shares surged over 10% to reach above $50. The company was granted a US patent titled "Load balancing across origin servers."

I'm looking forward to the company's Q3 report on November 3 because it will either confirm the bottom is in, or give me a chance to build a bigger position near $40.

The price and volume action certainly since May seem to suggest the worst selling is over, with a higher low near $37 in early October. Now we just have to see if analysts reverse their bearishness.

And in other supportive catalysts, on September 8 Evercore ISI put out a research note suggesting Akamai, Cloudflare, and Fastly may partner with Apple on its new service.

After Apple's recent announcement of its Private Relay service meant to offer enhanced security to iOS users, Evercore ISI analyst Amit Daryanani said he thinks the news is "notable and could be a positive for multiple companies."

The analyst believes that Apple has partnered with Akamai, Cloudflare and Fastly on the new iCloud+ Private Relay service, but he has "no sense on specific allocations" for each vendor.

Daryanani estimates that the traffic running through Private Relay could generate about $8 to $20 million in revenues in FY22 and views Private Relay as "an incremental positive for all companies involved."

Here's what I told my TAZR Trader group in the Buy Alert this week...

Portfolio is starting a very small starter position in Fastly under $50. We will add under $45 and $40 if those scenarios evolve. Basically, we take low risk now to get our keen attention and focus on the turn-around. And we add bigger if/when we get confirmation into their Q3 report on Nov 3.

Wall Street has grown to hate this tech growth stock after loving it too much last year. The summer outage for this streaming bandwidth provider didn't help.

I wrote about the growth implosion in my August Bear of the Day after their Q2 report. But here's what I said as I started licking my chops about the potential opportunity...

There seemed to be something of a capitulation-type move after last week's report with shares plunging to new 52-week lows under $35 on massive volume of 50 million shares, and then recovering $40 as if the worst might be discounted.

So I wouldn't blame you if you started to nibble under $40. I'm thinking about it myself with revenue growth still intact at 19% and looking to eclipse $400 million next year for a 12X forward sales multiple.

Unfortunately, we could never pull the trigger on FSLY near $40 because the stock remained trapped in the cellar of the Zacks Rank.

Well now somebody is accumulating, as Tuesday's 10.7% pop on 7.7 million shares will attest. The catalyst was news that the company was granted a US patent titled "Load balancing across origin servers."

And look how far behind Wall Street analysts are behind any recovery in this now Zacks #2 Rank...

I'm thinking the bottom is in for FSLY.

But I don't want to go all-in yet until we get analysts reversing and/or we get through the company's Q3 report and outlook.

(end of TAZR Buy Alert excerpt)

Still Doing the Volume

I perused the Fastly website this morning and they claim to be still moving small galaxies of data and content with 420 billion images optimized and delivered per month, 15 trillion log lines delivered per month, 800 billion requests per day, and greater than 95% customer satisfaction.

It's worth noting that Stripe, the next huge fintech IPO, is also a Fastly customer, according to the company website.

With FLSY shares at $50, it is now trading about 14 times next year's sales consensus of $405 million.

We'll know in a couple of weeks if customers like Apple and TikTok have had their faith restored and the growth rate for Fastly can reemerge above 20%.

Disclosure: I own shares of FSLY for the Zacks TAZR Trader portfolio.

Bear of the Day:

PagerDuty is a $3.6 billion provider of digital operations management solutions that address enterprise applications and systems performance.

The company offers a SaaS platform which helps developers, IT operations, and other cross-functional enterprise teams prevent and resolve business impacting incidents.

Here's how they describe their origins...

PagerDuty was founded by three innovative software developers who knew what it was like to carry the pager for "always on" cloud services. They made a bet that the early practice and culture of DevOps which encourages collaboration between development and operations would become strategic for every company.

What started as automating on-call rotations has evolved into a platform that helps companies of all sizes proactively manage their digital operations so their teams can spend less time reacting to incidents and more time building for the future.

In a sense, you could call PD a "first responder for DevOps."

After you read my Bull of the Day on Fastly, you might wonder if they are a customer now after that company's big outage "incident" in June.

Why PD is a Zacks #5 Rank?

While PD has been a serial upside earnings surpriser -- averaging +22% the last four quarters -- the earnings outlook took a decidedly different trajectory early this year.

To highlight the disappointment for some investors, FY22 (ends in January) is expected to record a loss 38-cents, representing an annual decline of 58% vs last year's -$0.24.

And insult to injury, while FY23 was projected to creep into profitability, the consensus now is for a loss of about 20 cents.

The good news is that revenues are still growing solidly in the 25-30% zone and the stock only trades at 11 times next year's consensus of $345 million. That makes it a bargain in cloud territory.

Bottom line on PD: A unique business model in an exploding industry with an impressive list of customers means I'm looking to buy PD on the dips once the growth outlook turns around. The Zacks Rank will let us know.

Additional content:

FDA Approves J&J and Moderna Covid Boosters, Mixing of Doses

The FDA has granted emergency use authorization (“EUA”) to booster doses of Johnson & Johnson’s single-shot COVID-19 vaccine and Moderna’s mRNA-based COVID-19 vaccine, mRNA-1273. The United States now has authorized booster doses of three COVID-19 vaccines. The third vaccine is Pfizer's mRNA-based vaccine, Comirnaty, whose booster dose was authorized by the FDA last month.

In an unexpected turn of events, the FDA also authorized the mix and match or heterologous administration of the booster doses of the three COVID-19 vaccines. The heterologous administration will allow inoculation of an individual with any of the three available booster jabs irrespective of the initial COVID-19 vaccine regimen.

Booster Dose Eligibility

J&J’s booster dose is now authorized for use in all adults who have completed at least two months of their primary vaccination with J&J’s single-shot COVID-19 vaccine. Moderna received authorization for emergency use of the booster dose of mRNA-1273 after at least six months of the initial two-dose regimen in people aged 65 years or older (elderly), and in adults aged 18 or older who at high risk of severe COVID-19 or whose exposure to COVID-19 puts them at a risk of complications or severe illness. Comirnaty’s booster dose is also authorized for a similar population and dosing interval as Moderna’s vaccine.

The mix-and-match administration will allow administration of J&J’s booster jab in elderly and high-risk adults who have received mRNA-1273 or Comirnaty during the initial regimen and after at least six months of primary vaccination. In a similar manner, the booster dose of mRNA-1273 or Comirnaty can be administered to all adults who have received J&J’s single-shot vaccine initially following a dosing interval of two months.

Shares of all the aforementioned COVID-19 vaccine makers were up in after-hours trading on Oct 20, following the unexpected heterologous administration authorizations.

Why Mix and Match?

The FDA authorized the mix and match administration based on clinical data from a study conducted by the National Institute of Allergy and Infectious Diseases (NIAID). The data demonstrated that the benefits of the use of a single heterologous booster dose outweigh risks.

Several health experts have been voicing support for the mix and match administration of booster doses for a better vaccination program. There have been cases of allergic reactions in individuals receiving a certain COVID-19 vaccine. Some regions in the United States do not have all the three booster vaccines available simultaneously.

The heterologous administration will alleviate these shortcomings. A person who has had a side-effect after receiving a mRNA-based vaccine can be administered J&J’s adeno-virus based booster vaccine and vice-versa. Moreover, the availability of any of the authorized booster doses in a region will allow the booster vaccination program to continue.

Also, the FDA’s authorization of heterologous administration will ease the concerns related to use of a different booster jab than the initial regimen.

While Pfizer carries a Zacks Rank #2 (Buy), Moderna and J&J carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

 

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Johnson & Johnson (JNJ) : Free Stock Analysis Report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
Moderna, Inc. (MRNA) : Free Stock Analysis Report
 
PagerDuty (PD) : Free Stock Analysis Report
 
Fastly, Inc. (FSLY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research